Wan Meixuan, Liang Xuan, Meng Jingwen, Wu Haiyao, Xi Chunhua
Department of Anesthesiology, Beijing Tongren Hospital, Capital Medical University, Beijing, People's Republic of China.
Operation Center, Beijing Tongren Hospital, Capital Medical University, Beijing, People's Republic of China.
J Pain Res. 2025 Jul 16;18:3627-3642. doi: 10.2147/JPR.S525231. eCollection 2025.
As a long-lasting local anesthetic, liposomal bupivacaine has become a part of certain multimodal analgesic regimens for acute postoperative pain. The objective of the present meta-analysis was to investigate the efficacy of liposomal bupivacaine in acute pain management after orthopedic surgery through peripheral nerve blocks and compare it with plain bupivacaine.
The EMBASE, PubMed, Web of Science, Scopus databases, the Cochrane Central Register of Controlled Trials, and the Cochrane Database of Systematic Reviews were searched for randomized controlled trials (RCTs) published in print or online up to 11 October 2024. The primary outcomes were NRS scores and opioid consumption at postoperative 24-72 hours. A minimum difference of 2.0 points on NRS scores or 30-mg in OME consumption was considered clinically relevant.
A total of 10 RCTs (782 patients) were finally included in the meta-analysis. There were significant differences in the mean NRS scores at postoperative 48 hours (MD = -0.86, 95% CI: [-1.19, -0.45], P < 0.001) and 72 hours (MD = -0.38, 95% CI: [-0.54, -0.21], P < 0.001). As regard to opioid consumption, there were statistical differences at postoperative 48 hours (MD = -5.51, 95% CI: [-9.97, -1.06], P = 0.020) and 72 hours (MD = -3.62, 95% CI: [-6.04, -1.21], P = 0.003). But none of the differences, including NRS scores and opioid consumption, met the prespecified thresholds for clinical relevance. Additional benefits of liposomal bupivacaine over plain bupivacaine were observed only in the nerve block duration (RR = 3.35, 95% CI: [1.92, 5.84], P < 0.001).
The advantages of perineural liposomal bupivacaine over plain bupivacaine in providing analgesia after orthopedic surgery were statistically significant but not clinically relevant. Current evidence suggests that the existing RCTs are insufficient to support the idea that the perineural use of liposomal bupivacaine is clinically worthwhile in pain management after orthopedic surgery compared with plain bupivacaine.
作为一种长效局部麻醉剂,脂质体布比卡因已成为某些急性术后疼痛多模式镇痛方案的一部分。本荟萃分析的目的是研究脂质体布比卡因在骨科手术后通过外周神经阻滞进行急性疼痛管理中的疗效,并将其与普通布比卡因进行比较。
检索了EMBASE、PubMed、Web of Science、Scopus数据库、Cochrane对照试验中央注册库和Cochrane系统评价数据库,以查找截至2024年10月11日发表的印刷版或在线随机对照试验(RCT)。主要结局是术后24至72小时的数字评分量表(NRS)评分和阿片类药物消耗量。NRS评分至少相差2.0分或阿片类药物消耗量相差30mg被认为具有临床相关性。
本荟萃分析最终纳入了10项RCT(782例患者)。术后48小时(MD = -0.86,95%CI:[-1.19,-0.45],P < 0.001)和72小时(MD = -0.38,95%CI:[-0.54,-0.21],P < 0.001)的平均NRS评分存在显著差异。在阿片类药物消耗量方面,术后48小时(MD = -5.51,95%CI:[-9.97,-1.06],P = 0.020)和72小时(MD = -3.62,95%CI:[-6.04,-1.21],P = 0.003)存在统计学差异。但包括NRS评分和阿片类药物消耗量在内的所有差异均未达到预先设定的临床相关性阈值。仅在神经阻滞持续时间方面观察到脂质体布比卡因比普通布比卡因有额外益处(RR = 3.35,95%CI:[1.92,5.84],P < 0.001)。
在骨科手术后提供镇痛方面,神经周围注射脂质体布比卡因优于普通布比卡因的优势具有统计学意义,但不具有临床相关性。目前的证据表明,现有的RCT不足以支持与普通布比卡因相比,神经周围使用脂质体布比卡因在骨科手术后疼痛管理中具有临床价值这一观点。